Aardvark Therapeutics, Inc. (NASDAQ: AARD) is facing a class action lawsuit filed in the Southern District of California, alleging securities law violations tied to its IPO and disclosures about its lead compound, ARD‑101. The suit comes after the company voluntarily paused its Phase 3 HERO trial in February 2026, followed by a full FDA clinical hold in May.
Aardvark is a clinical‑stage biopharma focused on metabolic diseases such as Prader‑Willi Syndrome (PWS), a rare condition marked by insatiable hunger. Unlike companies developing peptide drugs directly, Aardvark’s approach uses a small‑molecule agonist to activate bitter taste receptors (TAS2Rs) in the gut. This activation is designed to trigger secretion of endogenous peptides such as cholecystokinin (CCK) and glucagon‑like peptide‑1 (GLP‑1), both of which play critical roles in hunger suppression.
The lawsuit alleges that Aardvark overstated the safety and prospects of ARD‑101, failing to disclose cardiac safety concerns that later forced trial enrollment to pause. When the FDA imposed a full clinical hold, Aardvark’s stock dropped more than 30 percent, leaving shares well below the $16 IPO price.
For peptide‑focused readers, the case highlights an important distinction: while ARD‑101 is not itself a peptide therapy, its mechanism relies on peptide signaling pathways. GLP‑1 in particular has become a blockbuster target in obesity and diabetes drugs, and Aardvark’s strategy reflects the broader industry trend of leveraging peptide biology — whether through direct peptide drugs or small molecules that stimulate peptide release.
While cautious, the FDA has shown itself at least willing to find more information and later try and categorize peptides. This week, the FDA Pharmacy Compounding Advisory Committee (PCAC) recently held a highly publicized meeting to vote on recommending several popular wellness peptides for inclusion on the 503A Bulk Drug Substances List.
Yet the broader regulatory landscape remains complicated, it can be seen as a sign that peptide‑based innovation continues to gain traction.